MedTrace Logo

Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma

NCT06430424 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-07-30

No results posted yet for this study

Summary

Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.

Conditions

  • Relapsed Cancer
  • Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Interventions

BIOLOGICAL

Relapsed glioblastoma

Paired tumor samples diagnosis/relapse

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-05
Primary Completion
2025-07-31
Completion
2026-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06430424 on ClinicalTrials.gov